The Thymulin Peptide Needs Zinc to Work

The thymulin peptide is a nonapeptide hormone — a chain of nine amino acids — produced by the epithelial cells of the thymus, and its biological activity depends on a metal ion. The peptide alone is inert; the active molecule is a peptide–zinc complex. Strip the zinc away and thymulin stops registering in the assays that were built to detect it. That single fact, established in 1982, is the most durable thing anyone knows about this peptide, and it is why thymulin keeps surfacing in conversations about zinc, aging, and immune decline.

The rest of the picture is thinner than the peptide's reputation suggests. Thymulin was first described in the early 1970s under the name facteur thymique sérique (FTS), and the literature since then is a set of animal and cell-culture experiments — informative about mechanism, silent about people. There is no human thymulin trial: no human dose, no human outcome, no sample size. Every number below is labeled with the animal or the dish it came from, because that labeling is the article.

What the thymus does, and why it shrinks

The thymus is a small organ behind the sternum, between the lungs, and it is the primary site of T-cell maturation: progenitor cells from bone marrow migrate there and mature into T-lymphocytes. Inside, thymocytes are screened — cells that cannot recognize pathogens and cells that react against the body's own tissue are eliminated. That screening is where self-tolerance comes from, and its failure is what produces autoimmune disease. The thymus is also an endocrine organ, secreting thymulin alongside several other factors that act together during immune maturation.

Thymic involution begins shortly after puberty and continues for life, with functional tissue replaced by fat. The consequence is less new T-cell output and a narrower T-cell repertoire — immunosenescence — which is part of why older adults are more vulnerable to new infections such as influenza and respond less well to vaccines. Immune dysregulation with age also sustains chronic low-grade inflammation, "inflammaging," which feeds back into the decline (Fülöp et al., 2016).

A 2023 review of thymus aging identifies the three most prominent age-related changes as epithelial-structure disruption, adipogenesis, and thymocyte development arrest, and describes involution as multifactorial — regulated by FOXN1, FGF/KGF signaling, sex steroids, Notch, WNT, and microRNAs, with a documented sex disparity in how the thymus ages. Its leading reconstitution proposal is not a peptide at all: adoptive transfer of progenitor T cells generated in vitro, supported by cytokines and sex-steroid inhibition (Li and Zúñiga-Pflücker, 2023). Thymulin production declines substantially as this happens — but whether falling thymulin causes immune aging or simply accompanies it has not been settled.

Why zinc is not optional for thymulin

Thymulin's activity is conditional on zinc, and the demonstration is direct. In 1982, chelating metal ions out of serum thymic factor with Chelex 100 abolished its activity in a rosette assay; adding zinc salts back restored it, with a metal-to-peptide molar ratio of 1:1 giving the best activation. Other metals restored some activity, but less. The same work used atomic-absorption spectrometry to confirm zinc in the synthetic peptide and microanalysis to show zinc inside thymic reticuloepithelial cells — and it is where the name "thymulin" was proposed for the zinc-bound form (Dardenne et al., 1982). Zinc binds specific residues and drives a conformational change; the folded, zinc-loaded peptide is the one that engages receptors.

That dependency has a practical consequence. Because activity requires zinc rather than merely benefiting from it, zinc deficiency produces a functional thymulin deficiency: measurable thymulin activity falls even when peptide production is adequate, and zinc repletion restores activity (Dardenne and Pléau, 1994; Prasad, 2008). One proposed mechanism for the age-related failure involves zinc-bound metallothionein isoforms (I+II and III) sequestering zinc and impairing thymulin production — put forward as a hypothesis rather than a settled finding, and it is worth reading it that way (Mocchegiani et al., 2004).

You will also find claims circulating that thymulin is the only hormone requiring zinc for activity. That superlative has no source behind it, and it is not needed — the zinc dependence is interesting without it.

Every thymulin peptide finding so far is preclinical

There is no human efficacy or safety evidence for thymulin. The studies below are mouse, rat, and in vitro work, and they are the whole file. That matters twice over: it limits what anyone can honestly say about thymulin in people, and it explains the availability picture.

Promise does not offer thymulin. There is no thymulin product in the catalog and no waitlist page for one.

What the animal work does support is a consistent mechanistic story. Thymulin participates in intrathymic and extrathymic T-cell differentiation, guiding immature thymocytes toward mature functional T-cells and influencing the cell-surface markers that define helper, cytotoxic, and regulatory subsets (Reggiani et al., 2009). Descriptions of thymulin as a modulator rather than a booster — raising a response where it is deficient, damping it where it is excessive — fit that literature. Descriptions of it as "restoring Th1/Th2 balance" do not: no cited study reports that, and the nearest one found thymulin reduced the Th1 response in mice while leaving the Th17 response unaffected.

The inflammatory pathways thymulin acts on

Three converging pathways carry most of thymulin's anti-inflammatory signal in animals: NF-κB/RelA, p38 MAPK in spinal tissue, and broad restraint of circulating cytokines.

In severe experimental autoimmune encephalomyelitis, C57BL/6 mice immunized with myelin oligodendrocyte glycoprotein reach high lethality in roughly three weeks. Thymulin at 0.15 mg/kg intraperitoneally every other day reduced disease severity, attenuated the immune imbalance, and extended life-span, acting through inhibition of the RelA pathway and suppressing the Th1 rather than the Th17 response. Notably, co-administering thymulin with the NF-κB inhibitor IKK Inhibitor XII (1.8 mg/kg) produced no additive effect — the two behaved similarly, which argues against stacking them (Lunin et al., 2015).

In male NMRI mice challenged with lipopolysaccharide at 250 µg per 100 g body weight, thymulin pretreatment at 15 µg per 100 g body weight prevented plasma accumulation of IL-1β, IL-2, IL-6, TNF-α, and IFN-γ, and prevented endotoxin-induced cytokine upregulation by spleen lymphocytes and peritoneal macrophages. It also lowered the endotoxin-induced peak of heat-shock protein Hsp70, and added directly to LPS-stimulated macrophages in vitro it reduced the TNF-α peak. The challenge raised the anti-inflammatory cytokine IL-10 as well — the response being modulated, not switched off.

A relapsing-remitting model of experimental autoimmune encephalomyelitis, used as a multiple-sclerosis model, tested thymulin against blood–brain-barrier damage. Thymulin improved barrier integrity on three independent measures — Evans blue dye extravasation, preservation of tight-junction proteins, and reduced lymphocyte infiltration — and lowered serum IL-6, IL-17, and IFN-γ along with NF-κB cascade activation in splenocytes. One detail is easy to lose and shouldn't be: complete symptomatic restoration required thymulin together with peroxiredoxin 6. Prdx6 alone had no significant immunomodulatory effect, though it sharply reduced NOX1 and NOX4 expression in brain tissue (Lunin et al., 2023).

Thymulin's pain findings run in two directions

In a Complete Freund's Adjuvant model of inflammatory pain, rats treated intraperitoneally over 21 days showed reduced thermal hyperalgesia and paw edema, with suppression of spinal microglial activation, inhibited p38 MAPK phosphorylation, and lower spinal TNF-α and IL-6 (Nasseri et al., 2019). That is the result most often quoted, and quoted alone it is misleading.

The direction of thymulin's effect on pain depends on dose. At nanogram doses, thymulin given locally (intraplantar) or systemically is hyperalgesic in rats — it raises pro-inflammatory mediators and acts on capsaicin-sensitive primary afferent terminals through PGE2-dependent mechanisms. Analgesia and cytokine downregulation appear at relatively high systemic doses, 1–25 µg, or with the analogue PAT, which lacks the hyperalgesic effect and alleviated endotoxin-induced sickness behavior such as altered motor activity and fever. Delivered intracerebroventricularly, thymulin dose-dependently reduced endotoxin-induced hyperalgesia and inhibited NF-κB nuclear activation in the hippocampus (Dardenne et al., 2006). A molecule that flips sign with dose is a poor candidate for a simple story in either direction.

People often reach thymulin from two directions: immune aging, or inflammation. If it is the second, the closest thing in the live Promise catalog is KLOW, a four-peptide blend of BPC-157, GHK-Cu, KPV, and TB-500 — KPV being the short α-MSH fragment studied for inflammatory signaling. It is not a thymulin substitute and shares no mechanism with the thymic-peptide work above; it is a different set of compounds studied for different reasons.

Thymulin and the neuroendocrine-immune axis

The immune, nervous, and endocrine systems communicate constantly, and thymulin is one of the messengers in that network. The relationship is bidirectional and stated precisely in the source literature: the neuroendocrine system strongly influences thymulin production and secretion, and thymulin in turn acts as a hypophysiotropic peptide on the pituitary (Reggiani et al., 2009). The same review supports direct anti-inflammatory and analgesic activity for thymulin in brain tissue. Claims that go further — a characterized brain receptor, a specific HPA-axis mechanism buffering stress effects on immunity — are extrapolations, not findings in that paper.

The gene-therapy work sits on this branch. An adenoviral vector carrying a synthetic thymulin gene, injected stereotaxically into rat brain, expressed far longer than adenoviral transgenes usually do, which implies thymulin's own anti-inflammatory activity shielded the transduced cells from immune clearance. A synthetic sequence encoding the active analogue metFTS has been cloned into regulatable Tet-Off adenovectors that are doxycycline-reversible and co-express GFP, and thymulin gene therapy has been proposed to prevent endocrine, metabolic, and reproductive abnormalities in congenitally athymic (nude) mice, used as a model of neuroendocrine and reproductive aging (Reggiani et al., 2014).

Delivery is the practical obstacle, and one experiment addresses it well. A single intratracheal dose of thymulin-expressing plasmids in mucus-penetrating nanoparticles normalized the key pathological features of fully and stably established allergic asthma in mice — chronic inflammation, pulmonary fibrosis, and mechanical dysregulation — within 20 days, with tissue- and cell-level confirmation of anti-inflammatory and antifibrotic mediation (da Silva et al., 2020). It is the strongest single thymulin result on record, and it is a mouse study of a gene-delivery construct, not of an injected peptide.

Every route used in the cited literature is intraperitoneal, intratracheal, intraplantar, or intracerebroventricular. Descriptions of thymulin as a subcutaneous or intramuscular treatment are not grounded in any of the studies above.

Thymulin next to thymosin alpha-1

Thymulin and thymosin alpha-1 are both thymic peptides, and they are not interchangeable. Thymosin alpha-1 is longer, carries no metal requirement, and has human clinical research behind it; thymulin is shorter, inactive without zinc, and has none.

Thymic peptides as a class are also being examined in transplant medicine, where they are discussed in relation to T-cell expansion and immune reconstitution after allogeneic hematopoietic cell transplantation (Kunstek et al., 2025) — a review-level discussion, not a thymulin trial.

Promise's peptide medications, including thymosin alpha-1, are dispensed as compounded medications prepared by a licensed U.S. compounding pharmacy. Compounded thymosin alpha-1 is different from an FDA-approved product: the formulation offered here is not FDA-approved.

What else is being tried on the aging thymus

Thymulin is one candidate among several, and the more active frontiers are not peptide-based. The RANK–RANKL signaling axis deteriorates with age; endothelial cells depend on RANK signaling for cellularity and functional maturation, and declining RANKL availability degrades both endothelial and thymic epithelial compartments. Neutralizing RANKL in young mice mimicked involution, while giving RANKL to aged mice restored thymic architecture, endothelial and epithelial abundance and function, improved T-cell progenitor homing, increased T-cell production, and produced peripheral T-cell renewal with effective antitumor and vaccine responses. A proof-of-concept showed RANKL stimulating both cell types in human thymic organocultures (Santamaria et al., 2024).

A separate line implicates RNA modification. METTL3, an m6A methyltransferase enriched in double-positive (CD4+CD8+) thymocytes of young mice, declines with age; its loss permits ferroptosis through failure to maintain glutathione peroxidase 4 at the translational level, and double-positive thymocytes in aged mice acquire senescence features. Pharmacological ferroptosis inhibition promoted double-positive cell survival and attenuated aging features in those cells — a cellular rescue, not restored thymic function (Jing et al., 2024). A 2026 review frames involution as driven by hormonal modification and chronic inflammation altering the cross-talk between developing T cells and thymic epithelial cells, and notes that rejuvenation strategies have recently been identified (Santamaria and Irla, 2026).

Thymulin's place in immune support

Thymulin is a well-characterized molecule with a thin clinical file. The zinc dependence is real and elegantly demonstrated; the decline alongside thymic involution is real; the animal mechanism work on NF-κB, p38 MAPK, and cytokine restraint is real and specific. What does not exist is a single human study, which is why thymulin belongs in a discussion of immune-aging science rather than in a catalog. Promise does not offer it, and the compounded thymic peptide Promise does offer — thymosin alpha-1 — is a different molecule with a different evidence base, not a stand-in.

If immune support is what brought you here, the useful next step is a conversation with a clinician who can look at your history, your labs, and what you are trying to accomplish. A licensed provider reviews every request; not everyone qualifies, and a provider may decline.

This article is for informational purposes and is not medical advice.